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Abstract
Background: This study is an assessment of the impact of acquisition times on SUV with [18F]FDG-PET/CT on
healthy livers (reference organ with stable uptake over time) and on tumors.
Methods: One hundred six [18F]FDG-PET/CT were acquired in list mode over a single-bed position (livers (n = 48)
or on tumors (n = 58)). Six independent datasets of different durations were reconstructed (from 1.5 to 10 min). SUVmax
(hottest voxel), SUVpeak (maximum average SUV within a 1-cm
3 spherical volume), and SUVaverage were measured
within a 3-cm-diameter volume of interest (VOI) in the right lobe of the liver. For [18F]FDG avid tumors (SUVmax ≥ 5), the
SUVmax, SUVpeak, and SUV41% (isocontour threshold method) were computed.
Results: For tumors, SUVpeak values did not vary with acquisition time. SUVmax displayed significant differences
between 1.5- and 5–10-min reconstruction times. SUV41% was the most time-dependent parameter. For the
liver, the SUVaverage was the sole parameter that did not vary over time.
Conclusions: For [18F]FDG avid tumors, with short acquisition times, i.e., with new generations of PET systems, the
SUVpeak may be more robust than the SUVmax. The SUVaverage over a 3-cm-diameter VOI in the right lobe of the liver
appears to be a good method for a robust and reproducible assessment of the hepatic metabolism.
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Background
Assumed to be more accurate and less operator-
dependent than visual analysis, quantification is in-
creasingly used in positron emission tomography
(PET) studies in routine practice or clinical trials.
This is particularly relevant for treatment monitoring
since it has been shown that objective quantification
of [18F]FDG uptake changes may improve the prog-
nostic value of [18F]FDG-PET compared with visual
analysis [1]. Even prone to many sources of errors
and variability, the semi-quantitative method (stan-
dardized uptake value SUV) is currently preferred to
the absolute quantification of glucose metabolic rate,
which requires dynamic imaging and measurement of
the arterial input function, and thus considered to be
too complex for a use in routine practice. SUVmax
(SUV of the hottest voxel within a defined volume of
interest (VOI)) is the most widely used parameter,
easy-to-use, and operator-independent. However,
SUVmax may be affected by noise and may merely re-
flect statistical fluctuations when the acquisition time
is too short [2]. Among the other SUV, SUVpeak has
been suggested as an alternative to SUVmax [3]. SUVpeak is
an average SUV computed within a fixed-size VOI, most
often containing (and not necessarily centered on) the
hottest pixel value. Because this VOI encompasses several
pixels, SUVpeak is assumed to be less affected by image
noise than SUVmax [4, 5] and then more reliable and
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appropriate for monitoring tumor response, while
remaining easy-to-use with very little or no operator de-
pendency. The major drawback of SUVpeak is that its asso-
ciated volume of interest (VOIpeak) is not uniquely
defined, leading to a few dozen of SUVpeak definitions, dif-
fering in the shape, size, and location of the VOIpeak [6]. In
one hand, VOIpeak should be large enough to prevent
SUVpeak to be affected by noise and partial-volume effects,
and in other hand, VOIpeak should not be too large to
avoid inclusion of voxels outside the tumor. These consid-
erations lead to a fixed 1-cm3 sphere recommended by
PERCIST [3] as a standard definition of SUVpeak.
The use of time of flight (TOF) in reconstruction
algorithms of new generations of hybrid PET/CT ma-
chines (positron emission tomography scanner/X-ray
computed tomography scanner) improves signal-to-
noise ratio, spatial resolution, and lesion detectability,
theoretically allowing reduced injected activity (and
thus radiation exposure) and/or acquisition time [7].
Furthermore, point spread function (PSF) reconstruc-
tion, also available in new generations of PET sys-
tems, is known not only to improve sensitivity but
also to overestimate SUV [8, 9]. The quantitative ac-
curacy of these techniques is not fully known [8], es-
pecially their impact on the SUVmax determination
when acquisition time is reduced to its lower limit
for optimizing acquisition protocol in clinical practice.
The implementation of these new techniques there-
fore presents a challenge for centers to define an ac-
quisition protocol that can be used for visual and
quantitative analysis, while respecting the European
Association of Nuclear Medicine (EANM) guidelines
[10], i.e., either by determining the minimum FDG-
administrated dose in relation to PET acquisition dur-
ation and patient weight or by choosing to apply a
higher activity to reduce duration of the study. The
aim of this study was to evaluate the impact of acqui-
sition time on SUV on healthy livers (reference or-
gans with stable uptake over time) and on tumors.
Methods
Materials
One hundred six whole-body PET/CT scans with 2-
[18F]-2-deoxy-D-glucose ([18F]FDG) were performed in
102 patients (39 women, 63 men), for staging or for the
evaluation of treatment response of neoplastic or inflam-
matory diseases. Patients’ characteristics and tumor hist-
ology are summarized in Table 1. The Ethics Committee
of the University of Angers approved the study protocol.
PET/CT scanning
Patients fasted for at least 6 h before the intravenous in-
jection of 220 ± 57 MBq (3 MBq/kg) of [18F]FDG. Data
were acquired on a PET/CT Discovery-690 system
(LYSO scintillation PET detector; 64-slice CT; GE®, Buc,
France) with an acquisition time of 3 min/bed position.
PET images were reconstructed with an ordered-subset
expectation maximization (OSEM) 3D algorithm (3 iter-
ations, 8 subsets, 192 × 192 matrix, 3.65 mm pixels, slice
thickness 3.27 mm, post-reconstruction Gaussian 4 mm
filter) with VPFX time-of-flight (TOF) algorithm and
point spread function (PSF) correction (Sharp IR). CT-
based attenuation correction (120 kV, Auto mA, collima-
tion 20 mm, pitch 1.375, 0.8 s/rot) was applied.
Whole-body PET/CT were performed 62 ± 4.6 min
after [18F]FDG injection, and an additional PET/CT ac-
quisition of 10 min in list mode (LM) was acquired
using a single-bed position 83 ± 5.8 min after [18F]FDG
injection.
After the whole-body scan acquisitions (n = 106), add-
itional list mode acquisitions were performed on the most
avid tumor (tumor SUVmax > 5; n = 58) or on normal
healthy liver (no history of liver metastasis and no evi-
dence of liver lesion on whole-body [18F]FDG-PET/CT
scans; n = 48).
Six datasets (called R for replay) were reconstructed from
this LM additional acquisition, mimicking acquisition
Table 1 Patients characteristics: mean ± standard deviation
Characteristics All Women Men
Age 60 ± 17
Height (cm) 169 ± 10
Weight (kg) 69 ± 13.2
Body mass index (kg/m2) 24.2 ± 3.9 23.9 ± 4.2 24.4 ± 3.7
Injected activity (MBq) 220 ± 57
Whole-body PET/CT uptake time
(min post-injection)
62 ± 4.6
PET/CT uptake time for 10 min LM
acquisition (min post-injection)
83 ± 5.8
Tumor histology (n = 58)
Non-small cell lung cancer 29
Mesothelioma 1
Non-Hodgkin lymphoma including: 14
Diffuse B cell lymphoma 6
Follicular lymphoma 4
T cell lymphoma 2
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times of 1.5, 2, 2.5, 3, 5, and 10 min (respectively R1.5, R2,
R2.5, R3, R5, and R10).
Image analysis
Two experienced nuclear medicine physicians analyzed
all images datasets on an Imagys® workstation (Keosys®,
Saint-Herblain, France), allowing the computation of dif-
ferent SUV. SUV was corrected for body weight (SUVbw).
For tumor [18F]FDG uptake quantification, a manual
VOI encompassing the entire tumor was drawn on
R10. VOIs were registered and repositioned identically
for the five other replays (R1.5 to R5) using 3D coor-
dinates that allow the reposition of the VOI on all re-
plays. SUVmax (SUV of the hottest voxel), SUVpeak
(maximum average SUV within a 1-cm3 sphere),
SUV41% (threshold-based tumor delineation applying a
threshold of 41 % of the SUVmax), and metabolic
tumor volume (applying a threshold of 41 % of the
SUVmax on R10) were then automatically generated. A
threshold of 41 % was chosen following the EANM
guidelines [10] and because the most common thresh-
olding value chosen in the clinical setting is 40–43 %
of the SUVmax.
For the liver, a 14-cm3 VOI was positioned on the right
lobe of the liver on R10, as proposed in PERCIST [3]. As
for tumors, VOIs were repositioned identically for the five
other replays using 3D coordinates that allow the repos-
ition of the VOI on all replays. SUVmax, SUVpeak, and




For tumors, SUVmax, SUVpeak, and SUV41% were analyzed.
For livers, SUVmax, SUVpeak, and SUVaverage were analyzed.
Paired t tests were performed to study the inter-observer
reproducibility of tumor and liver measurements.
Repeated-measures ANOVA (Tukey post-tests) was
performed to test the variations of measurements over
time, i.e., between the six replays (R1.5 to R10).
Individual SUV fluctuations Δt over time (i.e., at 1.5, 2,
2.5, 3, and 5 min) were evaluated using the SUV at
10 min as reference SUV and were calculated as follows:
Δt ¼ SUVt−SUV10minð ÞSUV10min
For each replay, and for liver and tumors, the max-
imum individual fluctuations were registered.
Statistical tests were performed using Prism 4 software
(GraphPad software, CA, USA). The level of significance
was set at 5 %.
Results
No significant differences were observed between the two
readers for the evaluated image datasets (tumor and liver).
Tumors
SUVpeak was the only parameter stable over time with no
significant statistical difference between the six replays.
SUVmax and SUV41% decreased significantly with time
(p ≤ 0.0005) (Table 2). For SUVmax, statistical differences
were observed between the shortest acquisition time R1.5
versus the longest R5 and R10 (p = 0.0005).
SUV41% was the most time-dependent parameter,
with significant statistical differences between R1.5
and R2 versus R5 and R10 and between R2.5 and R10
(p < 0.0001) (Table 2).
SUVpeak was the least variable parameter with individ-
ual fluctuations up to 38 % (from 7.22 to 9.96) versus
58 % for SUVmax (from 10.82 to 17.1) and 56 % for
SUV41% (from 6.22 to 9.7) (Table 3). For all tumor SUVs,
maximal fluctuations were observed between the short-
est replay (R1.5 or R2) and R10. Considering a maximum
fluctuation of 10 % as an acceptable level of variation for
tumor SUV [11], the number of patients with tumor
SUV fluctuations >10 % (compared to R10) was noted.
R1.5 and R2 were the replays in which the higher number
of patients with SUV fluctuations >10 % was observed,
whatever the type of SUV. SUVpeak was the least variable















SUVmax 17.4 ± 9.5 (R5, R10) 17.3 ± 9.6 17.2 ± 9.7 17.1 ± 9.6 16.9 ± 9.5 16.9 ± 9.7 0.0005
SUV41% 10.4 ± 5.6 (R5, R10) 10.3 ± 5.5 (R5, R10) 10.2 ± 5.6 (R10) 10.2 ± 5.6 10.1 ± 5.5 10.1 ± 5.6 <0.0001
SUVpeak 13.6 ± 8.3 13.6 ± 8 13.6 ± 8.1 13.5 ± 8 13.6 ± 8.1 13.5 ± 8.2 NS
Liver
SUVmax 2.9 ± 0.5 (R2.5→ R10) 2.8 ± 0.5 (R3→ R10) 2.8 ± 0.5 (R5, R10) 2.7 ± 0.5 (R5, R10) 2.6 ± 0.5 (R10) 2.5 ± 0.5 <0.0001
SUVaverage 2.2 ± 0.4 2.2 ± 0.4 2.2 ± 0.4 2.2 ± 0.4 2.2 ± 0.4 2.2 ± 0.4 NS
SUVpeak 2.5 ± 0.4 (R2→ R10) 2.5 ± 0.4 (R5, R10) 2.4 ± 0.4 (R5, R10) 2.4 ± 0.4 (R5, R10) 2.4 ± 0.4 2.4 ± 0.4 <0.0001
(R2) means a significant difference with the replay R2, (R2.5) with R2.5, (R3) with R3, (R5) with R5, and (R10) with R10
Sher et al. EJNMMI Research  (2016) 6:21 Page 3 of 6
parameter with fluctuations >10 % observed in only five
patients (R1.5) compared to SUVmax (11 patients, R1.5)
and SUV41% (seven patients, R2).
Metabolic tumor volumes (VOI41%) measured on R10
varied widely from 1.1 to 369.32 cm3 (median 6.47 cm3).
Livers
SUVaverage was stable over time with no significant statis-
tical difference, whereas a significant tendency to de-
crease with time was observed for SUVmax and SUVpeak
(p ≤ 0.0005; Table 2).
For SUVpeak, statistical differences were observed be-
tween R1.5 and the other replays and between R2, R2.5,
and R3 versus R5 and R10 (p < 0.0001).
SUVmax was the most time-dependent parameter
(p < 0.0001) (Table 2).
SUVaverage was the least variable parameter with indi-
vidual variations up to 16 % (between R1.5 and R10) ver-
sus 19 % for SUVpeak and 41 % for SUVmax (between
R1.5 and R10).
Discussion
The SUV definitions used in the present study are usu-
ally described to be particularly suitable for response-
monitoring purposes. Indeed, these semi-automatic and
operator-independent methods allow a simple and re-
producible evaluation of SUV that is a basic requirement
to provide an added value to the quantitative measure-
ment compared to visual assessment. There is no actual
consensus about the best SUV parameter to be used to
assess response to therapy, but most response assess-
ment studies use SUVmax, the first reason being related
to its easy implementation and operator-independent
character. Moreover, for small lesions or during an ef-
fective treatment with a decrease in tumor size, when
partial-volume effect may result in an underestimation
of [18F]FDG uptake, SUVmax may be best suited as meta-
bolic index than the other SUVs [12]. In a clinical point
of view, identification of a suitable SUV for response
quantification requires clinical trials with patients’
clinical outcomes, and SUVmax demonstrated positive
predictive values and accuracies for outcome prediction
in lymphoma [1] as well as in solid tumors [13, 14]. Al-
though the increase in counting statistics with new
PET/CT systems contributes to reduce image noise,
SUVmax remains adversely affected by noise, leading to
uncertainty in the uptake quantification and thus in the
treatment response categorization. Theses inaccuracies
may be more pronounced in case of tumor heterogen-
eity that moreover may change during the course of
treatment [15]. Consequently, SUVpeak has been re-
cently proposed as a more robust alternative of SUVmax
[3]. SUVpeak has a larger volume compared to the single
pixel value of SUVmax and thus should be less affected
by image noise [4, 5, 16].
Acquisition times recommended by the manufacturer
are most often used in clinical routine, even though the
actual influence of acquisition time upon SUV is not
fully known. Regarding different quantifications of the
same metabolic process (for a given tumor), a correl-
ation does exist between SUVmax and SUVpeak and the
uncertainties of these two parameters are probably com-
parable, although from different causes [4]. Nevertheless,
these considerations do not allow an assessment of the
influence of acquisition time on SUV, and substantial
differences may exist between SUVmax and SUVpeak in
individual tumors that affect the treatment response
quantification and the response categorization.
Because the current worldwide trend is to reduce
patient exposure to ionizing radiation, it is not con-
ceivable to increase the injected activity to overcome
a low statistical quality of PET images due to a too
short acquisition time. Conversely, increasing the ac-
quisition time may lead to discomfort of the patient
and to motion artifacts. In our study, the highest fluc-
tuations of SUV were observed when acquisition
times were the shortest, whereas no significant differ-
ence was observed for replays superior or equal to
3 min. Brown et al. [17] investigated the effect of
varying acquisition times on phantom and patient
Table 3 Maximal individual SUV fluctuations (Δmax) compared to the reference SUV at 10 min
Δmax R1.5 vs R10 ( %) Δmax R2 vs R10 ( %) Δmax R2.5 vs R10 ( %) Δmax R3 vs R10 ( %) Δmax R5 vs R10 ( %) Δmax mean value ( %)
Tumor
SUVmax 58 43 31 24 31 37
SUV41% 56 41 26 25 26 35
SUVpeak 34 38 29 26 13 28
Liver
SUVmax 41 35 26 29 19 30
SUVaverage 16 15 14 14 9 14
SUVpeak 17 19 19 18 11 17
Δmax Rt-R10 (%) is the maximal individual fluctuation between SUV value at Rt and SUV value at R10. Δmax mean value is the mean Δmax from “R1.5 vs R10” to “R5
vs R10”
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PET images on a 3D GE Discovery-STE PET/CT sys-
tem. Patient data were investigated using list mode
acquisition to obtain comparable 2-, 3-, and 4-min
frames. As we reported for tumors, no significant dif-
ference was observed over 3 min at standard clinical
[18F]FDG activities. In two other studies, the image
quality was slightly adversely affected by an acquisi-
tion time of 1.5 min compared to 3 min [18] and the
volume and SUV variability were significantly larger
for images with scan times below 3 min [19].
For tumors, we did not observe any significant differ-
ence for SUVpeak over time, and regarding individual
variations, SUVpeak was also the least variable parameter.
Using a reference time of 15 min, Lodge et al. [20] re-
ported similar results with a significant lower bias for
the SUVpeak compared to the SUVmax for the 1-, 2-, 3-,
and 4-min images. In our study, large SUVmax variations
up to 58 % (R1.5 versus R10) were observed for the same
tumor in the same patient, which is obviously unaccept-
able for response-monitoring purposes, particularly
when accumulated to other sources of bias [11, 21] and
if a threshold value is applied to determine treatment re-
sponse as with PERCIST criteria [3]. As previously re-
ported [2, 4, 22], we noted that fluctuations of SUVmax
also affected threshold method SUV since the VOI was
determined by selecting pixel values equal to 41 % of the
maximum pixel value.
For all these reasons discussed, SUVpeak may be a ro-
bust alternative for the assessment of [18F]FDG avid
tumor uptake at standard clinical activities. We imple-
mented a SUVpeak algorithm using a fixed-size 1-cm
3
VOI, automatically positioned so as to maximize the
enclosed average (maximum average), typically including
but not necessarily centered on the maximum pixel
value. However, for small tumor sizes, the automatic
placement of the VOI may be impossible, but in these
cases, the placement of the VOI can be performed
manually.
Finally, an important additional result is the absence
of significant difference for the liver SUVaverage over
time. These results confirm that the liver metabolism
can be used as the reference organ for quality compari-
son of repeated [18F]FDG-PET studies in the same pa-
tient, or as a reference threshold for evaluating tumor
response. In PERCIST criteria, the size of the VOI and
its placement in the right lobe are mentioned, but not
the position to which the measure should be made.
However, a recent study found an excellent inter-observer
agreement and no significant difference whether the VOI
is placed in the upper part, the portal level, or at the bot-
tom of the right liver lobe [23]. Our results are also in
agreement with those of Grohien et al. [24], who showed a
larger dispersion of values and a higher variance for hep-
atic SUVmax compared to hepatic SUVaverage.
Conclusions
Tumor SUVpeak (volume 1 cm
3) was the most stable
quantitative parameter for acquisition times over 1.5 min
at standard clinical [18F]FDG activities.
Although not yet widely available, commercial devel-
opment of SUVpeak may increase the reproducibility and
accuracy of quantitative PET studies, this quality of
measure being essential for response-monitoring pur-
poses. Average SUV over a 3-cm VOI in the right liver
lobe was a good method for a robust assessment of hep-
atic metabolism, confirming the choice of the liver as
the reference organ in [18F]FDG studies.
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